openPR Logo
Press release

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review : Trends, Analysis, Growth and Status 2017

08-23-2017 11:35 AM CET | Health & Medicine

Press release from: Genetic Disorder

Genetic Disorder Cluster Muscular Dystrophy Drug Development

Albany, New York, August 23, 2017 : Recent research and the current scenario as well as future market potential of "Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017" globally.

This report provides an overview of the genetic disorders pipeline landscape, specifically focusing on muscular dystrophies. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Becker and Duchenne Muscular Dystrophy (BMD and DMD) and features dormant and discontinued projects. Both indications covered are inherited muscular dystrophies, a group of genetic, degenerative diseases primarily affecting voluntary muscles.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=1070457

BMD, the first type of muscular dystrophy, leads to symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls. DMD is a condition which causes muscle weakness, and is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

The size of these two pipelines ranges from just six in BMD to 108 in DMD. The majority of pipeline products for DMD target dystrophin which, as mentioned, is the causative gene for the disease. However, a number of products act on other molecular targets such as growth differentiation factor 8, nuclear factor kappa B and utrophin. The first two of these make up the pipeline for BMD, along with forkhead box protein 1B.

Scope

Which companies are the most active within the pipeline for genetic disorder therapeutics?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in the field of genetic disorder therapeutics?

Make an Enquiry about TOC @ http://www.researchmoz.us/enquiry.php?type=E&repid=1070457

Reasons to buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 5
List of Figures 7

Browse Report @ http://www.researchmoz.us/genetic-disorder-cluster-muscular-dystrophy-drug-development-pipeline-review-2017-report.html

Introduction 8
Genetic Disorder Cluster Muscular Dystrophy Report Coverage 8
Becker Muscular Dystrophy – Overview 8
Duchenne Muscular Dystrophy – Overview 8
Therapeutics Development 9
Becker Muscular Dystrophy 9
Duchenne Muscular Dystrophy 12
Therapeutics Assessment 22
Becker Muscular Dystrophy 22
Duchenne Muscular Dystrophy 30
Companies Involved in Therapeutics Development 38
Becker Muscular Dystrophy 38
Duchenne Muscular Dystrophy 40
Dormant Projects 63
Becker Muscular Dystrophy 63
Duchenne Muscular Dystrophy 64
Discontinued Products 66
Duchenne Muscular Dystrophy 66
Product Development Milestones 67
Duchenne Muscular Dystrophy 67

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review : Trends, Analysis, Growth and Status 2017 here

News-ID: 681257 • Views:

More Releases for Muscular

Limb Girdle Muscular Dystrophy Pipeline Insight 2025: Advancing Genetic and Rege …
DelveInsight's "Limb Girdle Muscular Dystrophy (LGMD) - Pipeline Insight, 2025" report provides a deep dive into the evolving therapeutic landscape of LGMD, a group of genetically inherited muscular disorders characterized by progressive weakness in the hip and shoulder muscles. With more than 25 active pipeline candidates targeting various LGMD subtypes, the field is witnessing a shift toward personalized gene therapies and precision treatments. Recent advances have focused on gene replacement, exon
Evolving Market Trends In The Spinal Muscular Atrophy Industry: Revolutionizing …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Expected Spinal Muscular Atrophy Market Size During the Forecast Period? Recent years have witnessed a swift expansion of the spinal muscular atrophy market size. The market is projected to surge from $3.53 billion in 2024 to $4.01 billion in 2025, escalating at a compound annual growth rate (CAGR) of 13.5%. The
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in
Becker Muscular Dystrophy Market Research Report 2032
DelveInsight's "Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Becker Muscular Dystrophy (BMD), historical and forecasted epidemiology as well as the Becker Muscular Dystrophy (BMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Becker Muscular Dystrophy (BMD) is an inherited muscle structure disorder that results in progressive deterioration of limbs, cardiac and skeletal muscles. However,
Increasing cases of Spinal Muscular Atrophy will accelerate the Spinal Muscular …
Precision Business Insights published a research report on "Spinal Muscular Atrophy Management Market: By Type of Disease (Type-I, Type-II, Type-III, Type-IV), By Management (Gene Therapy, Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2027", The Global Muscular Atrophy Management Market is anticipated to grow at considerable level during forecast period 2021-2027. Spinal Muscular Atrophy Management Market was valued at USD 1.3 Billion in 2020
Spinal Muscular Atrophy Market is Driven by Rising Number of People Affected wit …
The global spinal muscular atrophy market witnesses substantial competition with the presence of a considerable number of market participants of varying sizes, says Transparency Market Research (TMR) in a new market study. Read Report Overview - https://www.transparencymarketresearch.com/spinal-muscular-atrophy-market.html Savvy players are engaged in developing novel drug formulations, the success rate of which impacts market share, and trust of these companies among consumers. For such initiatives, large players are partnering with regional companies to